Total Payments
$1.5M
2024 Payments
$103,804
Companies
37
Transactions
1,264
Medicare Patients
1,299
Medicare Billing
$193,456
Payment Breakdown by Category
Other$963,524 (65.6%)
Consulting$300,947 (20.5%)
Travel$159,138 (10.8%)
Research$26,123 (1.8%)
Food & Beverage$17,887 (1.2%)
Education$407.67 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $936,184 | 276 | 63.8% |
| Consulting Fee | $300,947 | 122 | 20.5% |
| Travel and Lodging | $159,138 | 569 | 10.8% |
| Unspecified | $26,123 | 18 | 1.8% |
| Food and Beverage | $17,887 | 260 | 1.2% |
| Compensation for serving as faculty or as a speaker for a medical education program | $17,160 | 4 | 1.2% |
| Honoraria | $10,180 | 5 | 0.7% |
| Education | $407.67 | 10 | 0.0% |
Payments by Type
General
$1.4M
1,246 transactions
Research
$26,123
18 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $383,560 | 303 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $314,857 | 290 | $0 (2024) |
| Exelixis Inc. | $289,000 | 270 | $0 (2024) |
| PFIZER INC. | $124,301 | 96 | $0 (2024) |
| Astellas Pharma US Inc | $55,913 | 45 | $0 (2024) |
| GENZYME CORPORATION | $54,966 | 39 | $0 (2023) |
| Merck Sharp & Dohme LLC | $35,405 | 26 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $30,246 | 23 | $0 (2024) |
| Alkermes, Inc. | $25,344 | 20 | $0 (2023) |
| Genentech USA, Inc. | $22,577 | 22 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $103,804 | 91 | E.R. Squibb & Sons, L.L.C. ($44,596) |
| 2023 | $154,682 | 143 | Exelixis Inc. ($42,779) |
| 2022 | $145,555 | 130 | Bayer HealthCare Pharmaceuticals Inc. ($49,557) |
| 2021 | $88,841 | 53 | Exelixis Inc. ($35,950) |
| 2020 | $145,093 | 95 | E.R. Squibb & Sons, L.L.C. ($42,393) |
| 2019 | $302,013 | 267 | E.R. Squibb & Sons, L.L.C. ($97,414) |
| 2018 | $297,802 | 260 | E.R. Squibb & Sons, L.L.C. ($103,417) |
| 2017 | $230,236 | 225 | Bayer HealthCare Pharmaceuticals Inc. ($56,408) |
All Payment Transactions
1,264 individual payment records from CMS Open Payments — Page 1 of 51
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/04/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Consulting Fee | Cash or cash equivalent | $3,008.00 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Food and Beverage | In-kind items and services | $77.75 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Food and Beverage | In-kind items and services | $30.19 | General |
| Category: Oncology | ||||||
| 12/03/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Travel and Lodging | In-kind items and services | $204.94 | General |
| Category: Oncology | ||||||
| 12/03/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Travel and Lodging | In-kind items and services | $45.50 | General |
| Category: Oncology | ||||||
| 11/26/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Consulting Fee | Cash or cash equivalent | $3,100.00 | General |
| Category: HORMONE THERAPY | ||||||
| 11/25/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,290.00 | General |
| 11/24/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $86.91 | General |
| Category: Oncology | ||||||
| 11/04/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,290.00 | General |
| 11/04/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $915.00 | General |
| 10/15/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $7.56 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 10/10/2024 | AstraZeneca Pharmaceuticals LP | Truqap (Drug) | Consulting Fee | Cash or cash equivalent | $1,370.00 | General |
| Category: Oncology | ||||||
| 09/26/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Consulting Fee | Cash or cash equivalent | $3,625.00 | General |
| Category: Oncology | ||||||
| 09/14/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $168.82 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 09/13/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $55.25 | General |
| 09/13/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $13.87 | General |
| 08/27/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| Category: Oncology | ||||||
| 08/26/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $30.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 08/06/2024 | Exelixis Inc. | CABOMETYX (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $4,620.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 08/01/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $545.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 07/31/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $159.66 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 07/30/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $134.15 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 07/30/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | Cash or cash equivalent | $34.84 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 07/30/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | Cash or cash equivalent | $30.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 07/24/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $30.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| AXITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $13,670 | 7 |
| A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors | Millennium Pharmaceuticals, Inc. | $8,212 | 2 |
| PCYC-1128-CA | Pharmacyclics LLC, An AbbVie Company | $2,258 | 2 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $1,500 | 1 |
| A PHASE IB OPEN-LABEL, DOSE ESCALATION AND EXPANSION STUDY TO INVESTIG | GlaxoSmithKline, LLC. | $147.15 | 1 |
| RESEARCH RELATED PUBLICATION SUPPORT | Novartis Pharmaceuticals Corporation | $143.25 | 1 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF RAMUCIRUMAB PLUS DOCETAXEL VERSUS PLACEBO PLUS DOCETAXEL IN PATIENTS WITH LOCALLY ADVANCED OR UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA WHO PROGRESSED ON OR AFTER PLATINUM-BASED THERAPY | Eli Lilly and Company | $37.50 | 1 |
| A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors | ABBVIE INC. | $25.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 366 | 610 | $114,728 | $54,951 |
| 2022 | 6 | 369 | 644 | $99,336 | $59,117 |
| 2021 | 7 | 319 | 562 | $85,028 | $51,376 |
| 2020 | 4 | 245 | 408 | $98,833 | $28,012 |
Total Patients
1,299
Total Services
2,224
Medicare Billing
$193,456
Procedure Codes
33
All Medicare Procedures & Services
33 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 84 | 191 | $44,276 | $21,248 | 48.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 38 | 84 | $16,492 | $9,326 | 56.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 69 | 117 | $20,585 | $8,771 | 42.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 35 | 35 | $12,005 | $4,874 | 40.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 31 | 53 | $6,935 | $3,611 | 52.1% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 40 | 50 | $4,395 | $2,460 | 56.0% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 29 | 37 | $4,841 | $2,406 | 49.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 11 | 11 | $3,432 | $1,473 | 42.9% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2023 | 29 | 32 | $1,767 | $782.35 | 44.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 78 | 175 | $30,835 | $20,083 | 65.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 42 | 108 | $19,343 | $12,081 | 62.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 59 | 105 | $12,983 | $7,489 | 57.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 41 | 41 | $12,792 | $5,906 | 46.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 32 | 60 | $7,524 | $4,342 | 57.7% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 42 | 61 | $5,063 | $3,105 | 61.3% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 30 | 37 | $4,540 | $2,964 | 65.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 13 | 13 | $4,056 | $1,976 | 48.7% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2022 | 32 | 44 | $2,200 | $1,170 | 53.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 62 | 126 | $21,982 | $14,672 | 66.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 36 | 82 | $14,724 | $9,464 | 64.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 55 | 103 | $12,720 | $7,848 | 61.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 44 | 44 | $13,728 | $6,585 | 48.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 30 | 72 | $8,759 | $5,803 | 66.2% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 31 | 50 | $4,750 | $2,694 | 56.7% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 24 | 27 | $4,527 | $2,114 | 46.7% |
About Dr. Ulka Vaishampayan, MD
Dr. Ulka Vaishampayan, MD is a Medical Oncology healthcare provider based in Ann Arbor, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1659318640.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ulka Vaishampayan, MD has received a total of $1.5M in payments from pharmaceutical and medical device companies, with $103,804 received in 2024. These payments were reported across 1,264 transactions from 37 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($936,184).
As a Medicare-enrolled provider, Vaishampayan has provided services to 1,299 Medicare beneficiaries, totaling 2,224 services with total Medicare billing of $193,456. Data is available for 4 years (2020–2023), covering 33 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Internal Medicine
- Location Ann Arbor, MI
- Active Since 05/31/2006
- Last Updated 03/18/2020
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1659318640
Products in Payments
- OPDIVO (Biological) $321,398
- Xofigo (Drug) $196,115
- Cabometyx (Drug) $174,336
- Nubeqa (Drug) $107,026
- CABOMETYX (Drug) $101,585
- XTANDI (Drug) $68,564
- INLYTA (Drug) $47,006
- JEVTANA (Drug) $45,372
- TECENTRIQ (Biological) $34,226
- Xtandi (Drug) $24,719
- SUTENT (Drug) $20,882
- Bavencio (Biological) $19,923
- Lenvima (Drug) $19,067
- Trodelvy (Drug) $13,897
- VOTRIENT (Drug) $12,724
- ALUNBRIG (Drug) $8,437
- FOTIVDA (Drug) $7,983
- PLUVICTO (Drug) $7,572
- ORGOVYX (Drug) $5,700
- BAVENCIO (Drug) $5,515
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Ann Arbor
Sami Malek, Md, MD
Medical Oncology — Payments: $56,407
Medical Oncology $56,407
Erin Cobain, Md, MD
Medical Oncology — Payments: $33,857
Medical Oncology $33,857
Angel Qin, Md, MD
Medical Oncology — Payments: $28,858
Medical Oncology $28,858
Joshi Alumkal, Md, MD
Medical Oncology — Payments: $16,084
Medical Oncology $16,084
Scott Schuetze, Md, Phd, MD, PHD
Medical Oncology — Payments: $15,216
Medical Oncology $15,216
David Wang, Md, MD
Medical Oncology — Payments: $10,697
Medical Oncology $10,697